Quarterly report pursuant to Section 13 or 15(d)

Basis of Presentation and Summary of Significant Accounting Policies (Tables)

v3.23.1
Basis of Presentation and Summary of Significant Accounting Policies (Tables)
9 Months Ended
Mar. 31, 2023
Protein Sciences [Member] | QT Holdings Corporation [Member]  
Notes Tables  
Schedule of restructuring charges The related nine months ended March 31, 2023 restructuring charges were recorded in the income statement as follows (in thousands):

Employee

Asset

    

severance

    

impairment and other

    

Total

Selling, general and administrative

$

1,328

$

842

$

2,170

Employee

Asset

    

severance

    

impairment and other

    

Total

Expense incurred in the first quarter of 2023

$

1,328

$

842

$

2,170

Cash payments

(420)

(431)

(851)

Adjustments

(72)

(72)

Accrued restructuring actions balances as of September 30, 2022

908

339

1,247

Cash payments

(753)

(262)

(1,015)

Adjustments

(38)

(73)

(111)

Accrued restructuring actions balances as of December 31, 2022

117

4

121

Cash payments

(60)

(70)

(130)

Adjustments

(57)

75

18

Accrued restructuring actions balances as of March 31, 2023

$

$

9

$

9

Protein Sciences [Member] | Employee Severance [Member]  
Notes Tables  
Schedule of restructuring charges

Restructuring actions, including cash and non-cash impacts, are as follows (in thousands):

Employee

severance

Expense incurred in the second quarter of 2023

$

780

Cash payments

(176)

Adjustments

Accrued restructuring actions balances as of December 31, 2022

604

Cash payments

(586)

Adjustments

(18)

Accrued restructuring actions balances as of March 31, 2023

$

Diagnostics and Genomics [Member]  
Notes Tables  
Schedule of restructuring charges Total restructuring charges for the closure of the Exosome Diagnostics Germany facility for the year ended June 30, 2022 were recorded within Operating Income on the Income statement as follows (in thousands):

Employee

Asset

    

severance

    

impairment and other

    

Total

Selling, general and administrative

$

649

$

750

$

1,399

Restructuring actions, including cash and non-cash impacts, are as follows (in thousands):

Employee

Asset

    

severance

    

impairment and other

    

Total

Expense incurred in the first quarter of 2022

$

639

$

546

$

1,185

Incremental expense incurred during fiscal 2022

242

242

Cash payments

(589)

(554)

(1,143)

Adjustments(1)

(50)

(234)

(284)

Accrued restructuring actions balances as of June 30, 2022

$

$

$

(1)Adjustments include refinements to our estimated close down costs as well as the impacts from foreign currency exchange.